AFT Pharmaceuticals - Improving profitability
AFT recently announced an agreement with Baxter Healthcare to divest to Baxter some of its non-core and low-margin hospital products in New Zealand. An agreement for similar products is expected in Australia in the coming weeks. Once both are complete, the company expects the divestments to represent approximately 7.5% of operating revenue (likely between NZ$5m and NZ$6m). The divestments are expected to generate NZ$5m in cash and make a positive contribution of “several million dollars” to EBITDA. Whatever is lost in revenues is likely to be made up in higher overall gross margin, and lower sales and marketing expenses.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- AFT Pharmaceuticals - Improving profitability29 Mar 2018